INSM Q2 2023 Earnings — Insmed Incorporated Revenue & Financial Results | Market Cap Arena

INSMInsmed Incorporated

$31B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$77M+18.4% YoY

Gross Profit

$61M78.5% margin

Operating Income

-$236M-305.0% margin

Net Income

-$245M-317.0% margin

EPS (Diluted)

$-1.78

QoQ Revenue Growth

+18.4%

Cash Flow

Operating Cash Flow

-$123M

Free Cash Flow

-$128M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$1.6B

Stockholders' Equity

-$156M

Cash & Equivalents

$613M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$77M	$65M	+18.4%
Gross Profit	$61M	$49M	+24.2%
Operating Income	-$236M	-$88M	-166.7%
Net Income	-$245M	-$96M	-156.0%

Geographic Segments

UNITED STATES

$58M75%

JAPAN

$16M20%

Europe And The Rest Of The World

$4M5%